Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice

Amel Dudakovic, Emily T. Camilleri, Scott M. Riester, Christopher R. Paradise, Martina Gluscevic, Thomas M. O'Toole, Roman Thaler, Jared M. Evans, Huihuang Yan, Malayannan Subramaniam, John R. Hawse, Gary S. Stein, Martin A. Montecino, Meghan Elizabeth McGee Lawrence, Jennifer J. Westendorf, Andre J. Van Wijnen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Perturbations in skeletal development and bone degeneration may result in reduced bone mass and quality, leading to greater fracture risk. Bone loss is mitigated by bone protective therapies, but there is a clinical need for new bone-anabolic agents. Previous work has demonstrated that Ezh2 (enhancer of zeste homolog 2), a histone 3 lysine 27 (H3K27) methyltransferase, suppressed differentiation of osteogenic progenitors. Here, we investigated whether inhibition of Ezh2 can be leveraged for bone stimulatory applications. Pharmacologic inhibition and siRNA knockdown of Ezh2 enhanced osteogenic commitment of MC3T3 preosteoblasts. Next generation RNA sequencing of mRNAs and real time quantitative PCR profiling established that Ezh2 inactivation promotes expression of bone-related gene regulators and extracellular matrix proteins. Mechanistically, enhanced gene expression was linked to decreased H3K27 trimethylation (H3K27me3) near transcriptional start sites in genome-wide sequencing of chromatin immunoprecipitations assays. Administration of an Ezh2 inhibitor modestly increases bone density parameters of adult mice. Furthermore, Ezh2 inhibition also alleviated bone loss in an estrogen-deficient mammalian model for osteoporosis. Ezh2 inhibition enhanced expression of Wnt10b and Pth1r and increased the BMP-dependent phosphorylation of Smad1/5. Thus, these data suggest that inhibition of Ezh2 promotes paracrine signaling in osteoblasts and has boneanabolic and osteoprotective potential in adults.

Original languageEnglish (US)
Pages (from-to)24594-24606
Number of pages13
JournalJournal of Biological Chemistry
Volume291
Issue number47
DOIs
StatePublished - Nov 18 2016

Fingerprint

Ovariectomy
Osteogenesis
Bone
Bone and Bones
Paracrine Communication
Genes
RNA Sequence Analysis
Anabolic Agents
Enhancer of Zeste Homolog 2 Protein
Chromatin Immunoprecipitation
Extracellular Matrix Proteins
Bone Development
Methyltransferases
Phosphorylation
Regulator Genes
Osteoblasts
Histones
Bone Density
Small Interfering RNA
Lysine

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Dudakovic, A., Camilleri, E. T., Riester, S. M., Paradise, C. R., Gluscevic, M., O'Toole, T. M., ... Van Wijnen, A. J. (2016). Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice. Journal of Biological Chemistry, 291(47), 24594-24606. https://doi.org/10.1074/jbc.M116.740571

Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice. / Dudakovic, Amel; Camilleri, Emily T.; Riester, Scott M.; Paradise, Christopher R.; Gluscevic, Martina; O'Toole, Thomas M.; Thaler, Roman; Evans, Jared M.; Yan, Huihuang; Subramaniam, Malayannan; Hawse, John R.; Stein, Gary S.; Montecino, Martin A.; McGee Lawrence, Meghan Elizabeth; Westendorf, Jennifer J.; Van Wijnen, Andre J.

In: Journal of Biological Chemistry, Vol. 291, No. 47, 18.11.2016, p. 24594-24606.

Research output: Contribution to journalArticle

Dudakovic, A, Camilleri, ET, Riester, SM, Paradise, CR, Gluscevic, M, O'Toole, TM, Thaler, R, Evans, JM, Yan, H, Subramaniam, M, Hawse, JR, Stein, GS, Montecino, MA, McGee Lawrence, ME, Westendorf, JJ & Van Wijnen, AJ 2016, 'Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice', Journal of Biological Chemistry, vol. 291, no. 47, pp. 24594-24606. https://doi.org/10.1074/jbc.M116.740571
Dudakovic, Amel ; Camilleri, Emily T. ; Riester, Scott M. ; Paradise, Christopher R. ; Gluscevic, Martina ; O'Toole, Thomas M. ; Thaler, Roman ; Evans, Jared M. ; Yan, Huihuang ; Subramaniam, Malayannan ; Hawse, John R. ; Stein, Gary S. ; Montecino, Martin A. ; McGee Lawrence, Meghan Elizabeth ; Westendorf, Jennifer J. ; Van Wijnen, Andre J. / Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice. In: Journal of Biological Chemistry. 2016 ; Vol. 291, No. 47. pp. 24594-24606.
@article{9f4efbaf19b1422eac49112be0b9c862,
title = "Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice",
abstract = "Perturbations in skeletal development and bone degeneration may result in reduced bone mass and quality, leading to greater fracture risk. Bone loss is mitigated by bone protective therapies, but there is a clinical need for new bone-anabolic agents. Previous work has demonstrated that Ezh2 (enhancer of zeste homolog 2), a histone 3 lysine 27 (H3K27) methyltransferase, suppressed differentiation of osteogenic progenitors. Here, we investigated whether inhibition of Ezh2 can be leveraged for bone stimulatory applications. Pharmacologic inhibition and siRNA knockdown of Ezh2 enhanced osteogenic commitment of MC3T3 preosteoblasts. Next generation RNA sequencing of mRNAs and real time quantitative PCR profiling established that Ezh2 inactivation promotes expression of bone-related gene regulators and extracellular matrix proteins. Mechanistically, enhanced gene expression was linked to decreased H3K27 trimethylation (H3K27me3) near transcriptional start sites in genome-wide sequencing of chromatin immunoprecipitations assays. Administration of an Ezh2 inhibitor modestly increases bone density parameters of adult mice. Furthermore, Ezh2 inhibition also alleviated bone loss in an estrogen-deficient mammalian model for osteoporosis. Ezh2 inhibition enhanced expression of Wnt10b and Pth1r and increased the BMP-dependent phosphorylation of Smad1/5. Thus, these data suggest that inhibition of Ezh2 promotes paracrine signaling in osteoblasts and has boneanabolic and osteoprotective potential in adults.",
author = "Amel Dudakovic and Camilleri, {Emily T.} and Riester, {Scott M.} and Paradise, {Christopher R.} and Martina Gluscevic and O'Toole, {Thomas M.} and Roman Thaler and Evans, {Jared M.} and Huihuang Yan and Malayannan Subramaniam and Hawse, {John R.} and Stein, {Gary S.} and Montecino, {Martin A.} and {McGee Lawrence}, {Meghan Elizabeth} and Westendorf, {Jennifer J.} and {Van Wijnen}, {Andre J.}",
year = "2016",
month = "11",
day = "18",
doi = "10.1074/jbc.M116.740571",
language = "English (US)",
volume = "291",
pages = "24594--24606",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "47",

}

TY - JOUR

T1 - Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice

AU - Dudakovic, Amel

AU - Camilleri, Emily T.

AU - Riester, Scott M.

AU - Paradise, Christopher R.

AU - Gluscevic, Martina

AU - O'Toole, Thomas M.

AU - Thaler, Roman

AU - Evans, Jared M.

AU - Yan, Huihuang

AU - Subramaniam, Malayannan

AU - Hawse, John R.

AU - Stein, Gary S.

AU - Montecino, Martin A.

AU - McGee Lawrence, Meghan Elizabeth

AU - Westendorf, Jennifer J.

AU - Van Wijnen, Andre J.

PY - 2016/11/18

Y1 - 2016/11/18

N2 - Perturbations in skeletal development and bone degeneration may result in reduced bone mass and quality, leading to greater fracture risk. Bone loss is mitigated by bone protective therapies, but there is a clinical need for new bone-anabolic agents. Previous work has demonstrated that Ezh2 (enhancer of zeste homolog 2), a histone 3 lysine 27 (H3K27) methyltransferase, suppressed differentiation of osteogenic progenitors. Here, we investigated whether inhibition of Ezh2 can be leveraged for bone stimulatory applications. Pharmacologic inhibition and siRNA knockdown of Ezh2 enhanced osteogenic commitment of MC3T3 preosteoblasts. Next generation RNA sequencing of mRNAs and real time quantitative PCR profiling established that Ezh2 inactivation promotes expression of bone-related gene regulators and extracellular matrix proteins. Mechanistically, enhanced gene expression was linked to decreased H3K27 trimethylation (H3K27me3) near transcriptional start sites in genome-wide sequencing of chromatin immunoprecipitations assays. Administration of an Ezh2 inhibitor modestly increases bone density parameters of adult mice. Furthermore, Ezh2 inhibition also alleviated bone loss in an estrogen-deficient mammalian model for osteoporosis. Ezh2 inhibition enhanced expression of Wnt10b and Pth1r and increased the BMP-dependent phosphorylation of Smad1/5. Thus, these data suggest that inhibition of Ezh2 promotes paracrine signaling in osteoblasts and has boneanabolic and osteoprotective potential in adults.

AB - Perturbations in skeletal development and bone degeneration may result in reduced bone mass and quality, leading to greater fracture risk. Bone loss is mitigated by bone protective therapies, but there is a clinical need for new bone-anabolic agents. Previous work has demonstrated that Ezh2 (enhancer of zeste homolog 2), a histone 3 lysine 27 (H3K27) methyltransferase, suppressed differentiation of osteogenic progenitors. Here, we investigated whether inhibition of Ezh2 can be leveraged for bone stimulatory applications. Pharmacologic inhibition and siRNA knockdown of Ezh2 enhanced osteogenic commitment of MC3T3 preosteoblasts. Next generation RNA sequencing of mRNAs and real time quantitative PCR profiling established that Ezh2 inactivation promotes expression of bone-related gene regulators and extracellular matrix proteins. Mechanistically, enhanced gene expression was linked to decreased H3K27 trimethylation (H3K27me3) near transcriptional start sites in genome-wide sequencing of chromatin immunoprecipitations assays. Administration of an Ezh2 inhibitor modestly increases bone density parameters of adult mice. Furthermore, Ezh2 inhibition also alleviated bone loss in an estrogen-deficient mammalian model for osteoporosis. Ezh2 inhibition enhanced expression of Wnt10b and Pth1r and increased the BMP-dependent phosphorylation of Smad1/5. Thus, these data suggest that inhibition of Ezh2 promotes paracrine signaling in osteoblasts and has boneanabolic and osteoprotective potential in adults.

UR - http://www.scopus.com/inward/record.url?scp=84995739671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995739671&partnerID=8YFLogxK

U2 - 10.1074/jbc.M116.740571

DO - 10.1074/jbc.M116.740571

M3 - Article

C2 - 27758858

AN - SCOPUS:84995739671

VL - 291

SP - 24594

EP - 24606

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 47

ER -